Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286374493> ?p ?o ?g. }
- W4286374493 endingPage "21003" @default.
- W4286374493 startingPage "20991" @default.
- W4286374493 abstract "Zorifertinib (AZD-3759; ZFB) is a potent, novel, oral, small molecule used for the treatment of non-small cell lung cancer (NSCLC). ZFB is Epidermal Growth Factor Receptor (EGFR) inhibitor that is characterized by good permeability of the blood-brain barrier for (NSCLC) patients with EGFR mutations. The present research reports the profiling of in vitro, in vivo and reactive metabolites of ZFB. Prediction of vulnerable metabolic sites and reactivity pathways (cyanide and GSH) of ZFB were performed by WhichP450™ module (StarDrop software package) and XenoSite reactivity model (XenoSite Web Predictor-Home), respectively. ZFB in vitro metabolites were done by incubation with isolated perfused rat liver hepatocytes and rat liver microsomes (RLMs). Extraction of ZFB and its related metabolites from the incubation matrix was done by protein precipitation. In vivo metabolism was performed by giving ZFB (10 mg kg-1) through oral gavage to Sprague Dawley rats that were housed in metabolic cages. Urine was collected at specific time intervals (0, 6, 12, 18, 24, 48, 72, 96 and 120 h) from ZFB dosing. The collected urine samples were filtered then stored at -70 °C. N-Methyl piperazine ring of ZFB undergoes phase I metabolism forming iminium intermediates that were stabilized using potassium cyanide as a trapping agent. Incubation of ZFB with RLMs were performed in the presence of 1.0 mM KCN and 1.0 mM glutathione to check reactive intermediates as it is may be responsible for toxicities associated with ZFB usage. For in vitro metabolites there were six in vitro phase I metabolites, three in vitro phase II metabolites, seven reactive intermediates (four GSH conjugates and three cyano adducts) of ZFB were detected by LC-IT-MS. For in vivo metabolites there were six in vivo phase I and three in vivo phase II metabolites of ZFB were detected by LC-IT-MS. In vitro and in vivo phase I metabolic pathways were N-demethylation, O-demethylation, hydroxylation, reduction, defluorination and dechlorination. In vivo phase II metabolic reaction was direct sulphate and glucuronic acid conjugation with ZFB." @default.
- W4286374493 created "2022-07-21" @default.
- W4286374493 creator A5000788836 @default.
- W4286374493 creator A5013334740 @default.
- W4286374493 creator A5017902843 @default.
- W4286374493 creator A5029406424 @default.
- W4286374493 creator A5080398549 @default.
- W4286374493 date "2022-01-01" @default.
- W4286374493 modified "2023-09-26" @default.
- W4286374493 title "Profiling of <i>in vivo</i>, <i>in vitro</i> and reactive zorifertinib metabolites using liquid chromatography ion trap mass spectrometry" @default.
- W4286374493 cites W1189434757 @default.
- W4286374493 cites W1836485028 @default.
- W4286374493 cites W1879169560 @default.
- W4286374493 cites W1975540192 @default.
- W4286374493 cites W2033995711 @default.
- W4286374493 cites W2034953536 @default.
- W4286374493 cites W2046438390 @default.
- W4286374493 cites W2052792986 @default.
- W4286374493 cites W2054841768 @default.
- W4286374493 cites W2068701480 @default.
- W4286374493 cites W2075221169 @default.
- W4286374493 cites W2091053114 @default.
- W4286374493 cites W2106038133 @default.
- W4286374493 cites W2111900515 @default.
- W4286374493 cites W2141492546 @default.
- W4286374493 cites W2168242757 @default.
- W4286374493 cites W2210253908 @default.
- W4286374493 cites W2476056274 @default.
- W4286374493 cites W2501213466 @default.
- W4286374493 cites W2560000670 @default.
- W4286374493 cites W2562803393 @default.
- W4286374493 cites W2619134568 @default.
- W4286374493 cites W2738246471 @default.
- W4286374493 cites W2765641949 @default.
- W4286374493 cites W2781549999 @default.
- W4286374493 cites W2792565785 @default.
- W4286374493 cites W2883056996 @default.
- W4286374493 cites W2890583742 @default.
- W4286374493 cites W2892476255 @default.
- W4286374493 cites W2900981302 @default.
- W4286374493 cites W2901491542 @default.
- W4286374493 cites W3003855544 @default.
- W4286374493 cites W3008153600 @default.
- W4286374493 cites W4205297348 @default.
- W4286374493 cites W4210723770 @default.
- W4286374493 cites W4234236664 @default.
- W4286374493 cites W4246914745 @default.
- W4286374493 cites W615676984 @default.
- W4286374493 doi "https://doi.org/10.1039/d2ra02848d" @default.
- W4286374493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35919181" @default.
- W4286374493 hasPublicationYear "2022" @default.
- W4286374493 type Work @default.
- W4286374493 citedByCount "1" @default.
- W4286374493 countsByYear W42863744932022 @default.
- W4286374493 crossrefType "journal-article" @default.
- W4286374493 hasAuthorship W4286374493A5000788836 @default.
- W4286374493 hasAuthorship W4286374493A5013334740 @default.
- W4286374493 hasAuthorship W4286374493A5017902843 @default.
- W4286374493 hasAuthorship W4286374493A5029406424 @default.
- W4286374493 hasAuthorship W4286374493A5080398549 @default.
- W4286374493 hasBestOaLocation W42863744931 @default.
- W4286374493 hasConcept C147990577 @default.
- W4286374493 hasConcept C150903083 @default.
- W4286374493 hasConcept C170493617 @default.
- W4286374493 hasConcept C181199279 @default.
- W4286374493 hasConcept C185592680 @default.
- W4286374493 hasConcept C202751555 @default.
- W4286374493 hasConcept C207001950 @default.
- W4286374493 hasConcept C25642318 @default.
- W4286374493 hasConcept C2780026642 @default.
- W4286374493 hasConcept C43617362 @default.
- W4286374493 hasConcept C538909803 @default.
- W4286374493 hasConcept C55493867 @default.
- W4286374493 hasConcept C62231903 @default.
- W4286374493 hasConcept C86803240 @default.
- W4286374493 hasConcept C98274493 @default.
- W4286374493 hasConceptScore W4286374493C147990577 @default.
- W4286374493 hasConceptScore W4286374493C150903083 @default.
- W4286374493 hasConceptScore W4286374493C170493617 @default.
- W4286374493 hasConceptScore W4286374493C181199279 @default.
- W4286374493 hasConceptScore W4286374493C185592680 @default.
- W4286374493 hasConceptScore W4286374493C202751555 @default.
- W4286374493 hasConceptScore W4286374493C207001950 @default.
- W4286374493 hasConceptScore W4286374493C25642318 @default.
- W4286374493 hasConceptScore W4286374493C2780026642 @default.
- W4286374493 hasConceptScore W4286374493C43617362 @default.
- W4286374493 hasConceptScore W4286374493C538909803 @default.
- W4286374493 hasConceptScore W4286374493C55493867 @default.
- W4286374493 hasConceptScore W4286374493C62231903 @default.
- W4286374493 hasConceptScore W4286374493C86803240 @default.
- W4286374493 hasConceptScore W4286374493C98274493 @default.
- W4286374493 hasFunder F4320321145 @default.
- W4286374493 hasIssue "32" @default.
- W4286374493 hasLocation W42863744931 @default.
- W4286374493 hasLocation W42863744932 @default.
- W4286374493 hasLocation W42863744933 @default.
- W4286374493 hasOpenAccess W4286374493 @default.
- W4286374493 hasPrimaryLocation W42863744931 @default.